Table 1.
Summary of MAGE expression in select cancer types
| Percent of MAGE-positive patient tumors | ||||||
|---|---|---|---|---|---|---|
| MAGE a | Melanoma | Lung | Breast | Ovarian | HNSCC | References |
| A1 | 16–61% | 24–49% | 6% | 11–54% | 16–23% | [138, 139, 143, 146, 147, 149, 207] |
| A2 | 44–84% | 40% | 20% | 3% | 20–31% | [138, 149] |
| A3 | 48–80% | 38–55% | 10–26% | 3–37% | 29–41% | [42, 138, 141, 143, 147–150, 207] |
| A4 | 9–34% | 19–65% | 13–19% | 32–47% | 23–47% | [138, 139, 143, 147, 149, 207] |
| A6 | 48–82% | 26–50% | 28% | 5% | 31–43% | [42, 141, 148–150] |
| A8 | 4–9% | 7% | 4% | 3% | 1–3% | [208] |
| A9 | 8–23% | 69% | 16–45% | 25–37% | 25–33% | [144, 207] |
| A10 | 13–61% | 43% | 8% | 19–52% | 13–19% | [147, 207] |
| A11 | 15–41% | 61% | 8–67% | 33% | 18–38% | [208] |
| A12 | 45–77% | 27% | 9–15% | 5% | 13–28% | [208] |
| B1 | 4–23% | 9% | 25% | 8% | 0–7% | [208] |
| B2 | 10–27% | 41% | 3% | 8% | 19–35% | [151] |
| B3 | 0% | 0% | 1% | 5% | 1% | [208] |
| B4 | 0% | 0% | 3% | 0% | 0% | [208] |
| B6 | 18–25% | 55% | 1% | 5% | 20–27% | [150] |
| B16 | 6–21% | 6% | 21% | 1% | 1–4% | [208] |
| B18 | 9–20% | 9% | 4% | 18% | 1–5% | [208] |
| C1 | 24–62% | 28% | 5–38% | 16–35% | 9–13% | [138, 140, 143, 153, 207, 209] |
| C2 | 33–67% | 21% | 8–58% | 13% | 4–13% | [142, 209] |
a
MAGE expression correlates with DNA methylation status (highlight)